2025 - 6 Issue

Original article

New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening

Dana Tomčíková ORCID
Zuzana Prepiaková ORCID – Beáta Bušányová ORCID – Barbora Kostolná ORCID

Full Text links

DOI: 10.31348/2025/23

Published in Czech and Slovak Ophtalmology: 2025 - 6

Published on website: 30.05.2025

Keywords: ROP screening, recurrence of ROP, ROP recurrence screening, intravitreal treatment of ROP, follow-up monitoring of premature infants with ROP

Summary

Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.

References

  1. Fierson WM, et al. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics 2013;131(1):189-195.
  2. Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018;142(6):e20183061.
  3. Binenbaum G, Tomlinson LA, de Alba Campomanes AG, et al. Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria. JAMA Ophthalmol. 2020;138(1):31-37.
  4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol, 2003;121(12):1684-1694.
  5. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005; 123(7):991-999.
  6. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-1134.
  7. Costa MCD, Eckert GU, Fortes BGB,et al. Oral glucose for pain relief during examination for retinopathy of prematurity: a masked randomized clinical trial. Clinics. 2013;68(2):199-204.
  8. Lyu J, Zhang Q, Chen CL, et al. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors. Invest Ophthalmol Vis Sci. 2017;58(3):1719-1725.
  9. Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, et al., FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity. The FIREFLEYE Randomized Clinical Trial. JAMA. 2022;328(4):348-359.
  10. Patel N, Acaba-Berrocal L, Hoyek S, et al. Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity. A multicenter study. Ophthalmology. 2023;130(4):373-378.
  11. Ness P, Andaluz-Scher L, Leverant R, et al. Characteristics of spontaneously regressed retinopathy of prematurity at termination of acute retinal screening examinations using a novel grading system, J Pediatr Ophthalmol Strabismus. 2023;60(5):359-364.
  12. Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R. Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmologists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Guidelines. Early Hum Dev. 2023;Mar;177-
  13. doi: 10.1016/j.earlhumdev.2023.105715